Request a call
  1. Home
  2. Healthcare & Pharmaceuticals
  3. Reports Details

Global Theranostics Market [By Disease Type (Neurological Disorders, Cardiovascular Diseases, Oncology Disorders, and Immunological Disorders); By Technology (Polymerase Chain Reaction (PCR), In-situ Hybridization, Immunohistochemistry, and Sequencing); and by Regions]: Market size & Forecast, 2018 – 2026

Final Report will cover Impact of Covid-19 And Russia-Ukraine War

The Global Theranostics Market Size is anticipated to reach over USD 20.52 Billion by 2026 according to a new study published by Polaris Market Research.



Theranostics are defined as a combination of diagnostics and drug therapeutics to improve the drug safety, drug restructures development and effectiveness. The combination of effective medical drugs and advanced diagnostic tests has been given numerous names, such as Dx/Rx partnering, integrated medicine, pharmacodiagnostics, and companion diagnostics.



The increasing occurrence of life-threatening and chronic diseases and the demand for innovative chemotherapeutic treatments associated with the need for improving disease detection are the key factors propelling the global theranostics market. In addition, the rising potential of clinically adaptable nanomaterials in the biological imaging area and therapy is expected to bolster the market growth. Moreover, improved collaboration between drug and diagnostics firms are anticipated to enhance the growth of the theranostics market. In addition, a decrease in costs and reduced time required for medical trials monitored by pharmaceutical segments are another key drivers propelling the growth of the global theranostics market.



The global Theranostics Market is segmented on the basis of disease type, technology, and geography. On the basis of disease type, the global theranostics market is segmented into Neurological Disorders, Cardiovascular Diseases, Oncology Disorders, and Immunological Disorders. On the basis of disease type, the oncology segment is anticipated to boost the market growth. Increasing cancer cases and theranostics potentials to make effective cancer care are the factors associated with the market growth. On the basis of technology, the global theranostics market is segmented into Polymerase Chain Reaction (PCR), In-situ Hybridization, Immunohistochemistry, and sequencing. In 2017, the PCR is anticipated to dominate the market growth. The existence of a robust evaluate assortment in terms of polymerase chain reaction (PCR) is accountable for the larger market share.

Some major key players in global Theranostics Market include F Hoffman La Roche, Thermo Fisher Scientific Inc., GE Healthcare, Agilent Technologies, Qiagen NV, Foundation Medicine, Leica Biosystems Nussloch GmBH, and Pfizer, Inc. among others.

Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. Theranostics Market Insights
3.1. Theranostics – Industry snapshot
3.2. Theranostics - Ecosystem analysis
3.3. Theranostics Market dynamics
3.3.1. Theranostics – Market Forces
3.3.1.1. Theranostics Market driver analysis
3.3.1.2. Theranostics Market restraint/challenges analysis
3.3.1.3. Theranostics Market opportunity analysis
3.4. Industry analysis - Porter's five force
3.4.1. Bargaining power of supplier
3.4.2. Bargaining power of buyer
3.4.3. Threat of substitute
3.4.4. Threat of new entrant
3.4.5. Degree of competition
3.5. Theranostics Market PEST analysis, 2017
3.5.1. Theranostics Industry trends
3.5.2. Competitive Ranking Analysis
4. Theranostics Market Size and Forecast by Disease Type
4.1. Key findings
4.2. Neurological Disorders
4.2.1. Global market estimates and forecasts, 2017 – 2026
4.3. Cardiovascular Diseases
4.3.1. Global market estimates and forecasts, 2017 – 2026
4.4. Oncology Disorders
4.4.1. Global market estimates and forecasts, 2017 – 2026
4.5. Immunological Disorders
4.5.1. Global market estimates and forecasts, 2017 – 2026
5. Theranostics Market Size and Forecast by Technology
5.1. Key findings
5.2. Polymerase Chain Reaction (PCR)
5.2.1. Global market estimates and forecasts, 2017 - 2026
5.3. In-situ Hybridization
5.3.1. Global market estimates and forecasts, 2017 – 2026
5.4. Immunohistochemistry
5.4.1. Global market estimates and forecasts, 2017 – 2026
5.5. Sequencing
5.5.1. Global market estimates and forecasts, 2017 – 2026
6. Theranostics Market Size and Forecast by Regions
6.1. Key findings
6.2. North America
6.2.1. Theranostics Market by Disease Type, 2017 - 2026
6.2.2. Theranostics Market by Technology, 2017 - 2026
6.2.3. U.S.
6.2.3.1. Theranostics Market by Disease Type, 2017 - 2026
6.2.3.2. Theranostics Market by Technology, 2017 - 2026
6.2.4. Canada
6.2.4.1. Theranostics Market by Disease Type, 2017 - 2026
6.2.4.2. Theranostics Market by Technology, 2017 - 2026
6.3. Europe
6.3.1. Theranostics Market by Disease Type, 2017 - 2026
6.3.2. Theranostics Market by Technology, 2017 - 2026
6.3.3. Germany
6.3.3.1. Theranostics Market by Disease Type, 2017 - 2026
6.3.3.2. Theranostics Market by Technology, 2017 - 2026
6.3.4. UK
6.3.4.1. Theranostics Market by Disease Type, 2017 - 2026
6.3.4.2. Theranostics Market by Technology, 2017 - 2026
6.3.5. France
6.3.5.1. Theranostics Market by Disease Type, 2017 - 2026
6.3.5.2. Theranostics Market by Technology, 2017 - 2026
6.3.6. Italy
6.3.6.1. Theranostics Market by Disease Type, 2017 - 2026
6.3.6.2. Theranostics Market by Technology, 2017 - 2026
6.4. Asia Pacific
6.4.1. Theranostics Market by Disease Type, 2017 - 2026
6.4.2. Theranostics Market by Technology, 2017 - 2026
6.4.3. China
6.4.3.1. Theranostics Market by Disease Type, 2017 - 2026
6.4.3.2. Theranostics Market by Technology, 2017 - 2026
6.4.4. India
6.4.4.1. Theranostics Market by Disease Type, 2017 - 2026
6.4.4.2. Theranostics Market by Technology, 2017 - 2026
6.4.5. Japan
6.4.5.1. Theranostics Market by Disease Type, 2017 - 2026
6.4.5.2. Theranostics Market by Technology, 2017 - 2026
6.4.6. Australia
6.4.6.1. Theranostics Market by Disease Type, 2017 - 2026
6.4.6.2. Theranostics Market by Technology, 2017 - 2026
6.5. Latin America
6.5.1. Theranostics Market by Disease Type, 2017 - 2026
6.5.2. Theranostics Market by Technology, 2017 - 2026
6.5.3. Brazil
6.5.3.1. Theranostics Market by Disease Type, 2017 - 2026
6.5.3.2. Theranostics Market by Technology, 2017 - 2026
6.5.4. Mexico
6.5.4.1. Theranostics Market by Disease Type, 2017 - 2026
6.5.4.2. Theranostics Market by Technology, 2017 - 2026
6.6. Middle East & Africa
6.6.1. Theranostics Market by Disease Type, 2017 - 2026
6.6.2. Theranostics Market by Technology, 2017 - 2026
7. Company Profiles
7.1. F Hoffman La Roche
7.1.1. Overview
7.1.2. Financials
7.1.3. Product Benchmarking
7.1.4. Recent Developments
7.2. Thermo Fisher Scientific Inc.
7.2.1. Overview
7.2.2. Financials
7.2.3. Product Benchmarking
7.2.4. Recent Developments
7.3. GE Healthcare
7.3.1. Overview
7.3.2. Financials
7.3.3. Product Benchmarking
7.3.4. Recent Developments
7.4. Agilent Technologies
7.4.1. Overview
7.4.2. Financials
7.4.3. Product Benchmarking
7.4.4. Recent Developments
7.5. Qiagen NV
7.5.1. Overview
7.5.2. Financials
7.5.3. Product Benchmarking
7.5.4. Recent Developments
7.6. Foundation Medicine
7.6.1. Overview
7.6.2. Financials
7.6.3. Product Benchmarking
7.6.4. Recent Developments
7.7. Leica Biosystems Nussloch GmBH
7.7.1. Overview
7.7.2. Financials
7.7.3. Product Benchmarking
7.8. Pfizer, Inc.
7.8.1. Overview
7.8.2. Financials
7.8.3. Product Benchmarking
7.8.4. Recent Developments

List of Figures
Report Id:
PMR-10065
Category:
Healthcare & Pharmaceuticals
Published On:
May 2018
Pages: 90

Report Price

  • Single User $ 3950.00
  • Multi User $ 4950.00
  • Corporate User $ 5950.00
Request For Sample Request For Customization
Why Choose Us
  • One Stop Solution Provider
  • Dedicated Client Support
  • Data Protection and Privacy
  • Cost Efficiency
  • Years of Experience
  • Worldwide Clientele Existence